Lipid nephrotoxicity: New concept for an old disease

Current Hypertension Reports

Volumn 14, Issue 2, 2012, Pages 177-181

  Gyebi, Leonard ^a   Soltani, Zohreh ^a   Reisin, Efrain ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chronic kidney disease; Diabetes; Dyslipidemia; End stage renal disease; ESRD; HDL; LDL; Lipid nephrotoxicity; Lipids; Management; Nephrotoxicity; Obesity; Pathophysiology; Progression; Statins

Indexed keywords

ALBUMIN; ATORVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TESAGLITAZAR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; GLOMERULOSCLEROSIS; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; INTERSTITIAL NEPHRITIS; ISCHEMIC HEART DISEASE; LIPID NEPHROTOXICITY; METABOLIC DISORDER; MICROALBUMINURIA; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA;

ARRHYTHMIAS, CARDIAC; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; KIDNEY DISEASES; LIPID METABOLISM; LIPID METABOLISM DISORDERS; OBESITY; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84861096120     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0250-2     Document Type: Article

References (34)

1. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney diease. Clin J Am Soc Nephrol. 2007;2:550-62.
2. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713-21.
3. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-79.
4. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of highdensity lipoprotein in chronic kidney disease. Transl Res. 2009;153:77-85.
5. Liu Y, Coresh J, Eustance J, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-9. (Pubitemid 38129749)
6. Cases A, Elisabeth C. Dyslipidemia and the progression of renal disease in chronic renal failure. Kidney Int. 2005;68:87-93.
7. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int. 1981;19:625-37. (Pubitemid 11064667)
8. Moorhead JF, Chan MK, el-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitialdisease. Lancet. 1982;2:1309-11. (Pubitemid 13240921)
9. Mahley RW. Atherogenic hyperlipoproteinemia. Med Clin North Am. 1982;66:75-402.
10. Lee HS, Jeong JY, Kim BC. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 1997;51:1151-9. (Pubitemid 27186541)
11. Misra RP, Berman LB. Studies in glomerular basement membrane II isolation and characterization of disease glomerular basement membrane. Lab Invest. 1965;18:1-35.
12. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis. 2000;36:272-81. (Pubitemid 30485835)
13. Fox CS, Larson MG, Leip EP, Culleton B. Predictors of new onset kidney disease in a community-based population. JAMA. 2004;291:844-50. (Pubitemid 38543772)
14. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities. Kidney Int. 2000;58:293-301. (Pubitemid 30429874)
15. Manttari M, Tiula E, Alikoski T, et al. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26:670-5.
16. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084-91. (Pubitemid 36909916)
17. Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in participants with non-insulin dependent diabetes mellitus: prospective observational study. Br Med J. 1997;314:783-8. (Pubitemid 27117048)
18. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998-1004. (Pubitemid 28213577)
19. Reisin E, Liao J, Ebenezer P, et al. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese Zucker rats fed with an atherogenic diet. Am Med Sci. 2009;338(4):301-9.
20. Tonelli M, Moye L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605-13. (Pubitemid 36687063)
21. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-9. (Pubitemid 32055234)
22. Athyros VG, Papageorgiou AA, Elisaf M, et al. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615-7. (Pubitemid 37288068)
23. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361: 2005-16.
24. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565-70. (Pubitemid 36278373)
25. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102:52-60. (Pubitemid 38490263)
26. Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoproteininduced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000;267:536-40. (Pubitemid 30076833)
27. Chmielewski M, Bryl E, Marzec L, et al. Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs. 2005;29:608-14. (Pubitemid 41602837)
28. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002;45:147-54. (Pubitemid 35425654)
29. Vamvakopoulos JE, Green C. HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statinmediated vasculoprotection. BMC Cardiovasc Disord. 2003;3:6.
30. Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15:1616-22. (Pubitemid 38679687)
31. Bussolati B, DeregibuS MC, Fonsato V, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating phosphatidylinositol 3-kinase/AKT-signalling pathway. J Am Soc Nephrol. 2005;16:1936-47. (Pubitemid 41716424)
32. O'Brien PE, Dixon JB, Laurie C, et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med. 2006;144:625-33. (Pubitemid 46780646)
33. Thakur V,Morse S, Reisin E. Functional and structural renal changes in the early stages of obesity. Contrib Nephrol. 2006;151:135-50. (Pubitemid 44298228)
34. Liao J, Soltani Z, Ebenezer P, et al. Tesaglitazar, a dual peroxisome proliferator activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp Nephrol. 2010;114:55-62.